A5038171562- Advanced Neuroimaging Techniques and Applications
- Childhood Cancer Survivors' Quality of Life
- interferon and immune responses
- Ethics and Legal Issues in Pediatric Healthcare
- BRCA gene mutations in cancer
- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Genetic Neurodegenerative Diseases
- Cancer, Lipids, and Metabolism
- Adipokines, Inflammation, and Metabolic Diseases
- Cytokine Signaling Pathways and Interactions
- Mitochondrial Function and Pathology
Center for Cancer Research
2024
Harvard University
2023-2024
Massachusetts General Hospital
2024
Johns Hopkins University
2021
University of Iowa
2020
Abstract Chronic inflammation is a major cause of cancer worldwide. Interleukin 33 (IL-33) critical initiator cancer-prone chronic inflammation; however, its induction mechanism by environmental causes unknown. Herein, we demonstrate that Toll-like receptor (TLR)3/4-TBK1-IRF3 pathway activation links insults to IL-33 in the skin and pancreas inflammation. An FDA-approved drug library screen identifies pitavastatin effectively suppress expression blocking TBK1 membrane recruitment/activation...
Spinocerebellar ataxia type 1 is a progressive neurodegenerative, movement disorder. With potential therapies on the horizon, it critical to identify biomarkers that (i) differentiate between unaffected and spinocerebellar Type 1-affected individuals; (ii) track disease progression; (iii) are directly related clinical changes of patient. Magnetic resonance imaging volumetric in brain may be suitable source for 1. In previous report longitudinal study patients with 1, we evaluated volume...
<h3>Background</h3> PARP inhibitors (PARPi) have shown significant improvement in PFS compared to chemotherapy patients with <i>BRCA1/2</i>m advanced breast cancer (ABC). However, response durability remains a challenge. PARPi activates the cGAS-STING pathway, leading increased PD-L1 expression and cytotoxic T-cell recruitment, potentially rendering tumors more susceptible immunotherapy. <h3>Methods</h3> The TALAVE trial (NCT03964532) enrolled two cohorts: cohort 1 included <i>BRCA1/2</i>m,...
Many pediatric oncology patients and their families may benefit from genetic counseling testing; however, identifying the best timing delivery method for these referrals is sometimes a challenge. The goal of this study was to understand how when caregivers prefer receive information about testing. A total 56 surveys completed by at Johns Hopkins Hospital Pediatric Oncology unit in Baltimore, Maryland were analyzed. sizeable subset respondents interested receiving availability an doctor or...